Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) EBT (2022 - 2025)

Historic EBT for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • 60 Degrees Pharmaceuticals' EBT fell 724.63% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 31.1%. This contributed to the annual value of -$8.0 million for FY2024, which is 10860.91% down from last year.
  • According to the latest figures from Q3 2025, 60 Degrees Pharmaceuticals' EBT is -$2.3 million, which was down 724.63% from -$1.7 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year EBT high stood at $4.2 million for Q3 2023, and its period low was -$4.2 million during Q2 2024.
  • Its 4-year average for EBT is -$1.6 million, with a median of -$2.0 million in 2023.
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' EBT soared by 38775.21% in 2023, and later tumbled by 53855.78% in 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' EBT (Quarter) stood at -$1.7 million in 2022, then decreased by 22.53% to -$2.0 million in 2023, then dropped by 0.16% to -$2.0 million in 2024, then fell by 13.05% to -$2.3 million in 2025.
  • Its EBT stands at -$2.3 million for Q3 2025, versus -$1.7 million for Q2 2025 and -$1.9 million for Q1 2025.